Program
tegoprubart
Also written as “AT-1501”, “Tegoprubart” and “AT-1501 IV Infusion”.
Its studies are mostly in Kidney Failure, Chronic · Diabetes Mellitus, Type 1 · Glomerulonephritis, IGA · Amyotrophic Lateral Sclerosis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eledon Pharmaceuticals | 63 open or running | phase 3since Sep 16, 2026 | Aug 19, 2021 | Jan 2027phase 2 · NCT05027906 |
| Anelixis Therapeutics | 20 open or running | phase 2since Mar 20, 2020 | Mar 20, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 20, 2020First study: phase 2 study in Amyotrophic Lateral SclerosisNew to Anelixis TherapeuticsAnelixis Therapeutics · NCT04322149 · 54 enrolled · United States, Canada
- Jan 10, 2021Phase 2 study in Diabetes Mellitus, Type 1Anelixis Therapeutics · NCT04711226 · Canada
- Aug 19, 2021Eledon Pharmaceuticals's first study: phase 2 study in Kidney Failure, ChronicNew to Eledon PharmaceuticalsEledon Pharmaceuticals · NCT05027906 · 48 planned · United States, Australia, Brazil and more
- Nov 8, 2021Phase 2 study in Glomerulonephritis, IGAEledon Pharmaceuticals · NCT05125068 · 24 enrolled · Australia, Croatia, Malaysia and more
- Jul 27, 2022Phase 2 study in Diabetes Mellitus, Type 1Eledon Pharmaceuticals · NCT05480657 · United States
- Aug 2, 2023Phase 2 study in Kidney Failure, ChronicEledon Pharmaceuticals · NCT05983770 · 127 enrolled · United States, Australia, Brazil and more
- Nov 6, 2023Phase 2 study in Kidney Failure, ChronicEledon Pharmaceuticals · NCT06126380 · 132 planned · United States, Australia, Brazil and more
- Sep 16, 2026Phase 3 study in Kidney Failure, ChronicPhase 3 reachedEledon Pharmaceuticals · NCT07835581 · 620 planned
Ahead
- Jan 2027Primary completion: phase 2 study in Kidney Failure, ChronicEledon Pharmaceuticals · NCT05027906
- Mar 2029Primary completion: phase 3 study in Kidney Failure, ChronicEledon Pharmaceuticals · NCT07835581
- Dec 2029Primary completion: phase 2 study in Kidney Failure, ChronicEledon Pharmaceuticals · NCT06126380
TargetBeta
“CD40 ligand inhibitor”ChEMBL 37, by rule
Other programs on CD40LG
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| frexalimab | Sanofi | phase 3 | 11 |
| dazodalibeprule | Amgen | phase 3 | 9 |
| dapirolizumab pegolrule | UCB | phase 3 | 8 |
| ravagalimabrule | AbbVie | phase 2 | 4 |
| OPT101rule | op-t-llc | phase 2 | 4 |
| TNX-1500rule | Tonix Pharmaceuticals | phase 1 | 1 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07835581Kidney Failure, Chronic | 3 | Not yet recruiting | Eledon Pharmaceuticals | Mar 2029 | 620 |
| NCT06126380Kidney Failure, Chronic · United States, Australia, Brazil and more | 2 | By invitation | Eledon Pharmaceuticals | Dec 2029 | 132 |
| NCT05983770Kidney Failure, Chronic · United States, Australia, Brazil and more | 2 | Completed | Eledon Pharmaceuticals | Sep 11, 2025 | 127 |
| NCT05480657Diabetes Mellitus, Type 1 · United States | 2 | Withdrawn | Eledon Pharmaceuticals | Aug 2024 | 0 |
| NCT05125068Glomerulonephritis, IGA · Australia, Croatia, Malaysia and more | 2 | Terminated | Eledon Pharmaceuticals | Jul 31, 2023 | 24 |
| NCT05027906Kidney Failure, Chronic · United States, Australia, Brazil and more | 2 | Recruiting | Eledon Pharmaceuticals | Jan 2027 | 48 |
| NCT04711226Diabetes Mellitus, Type 1 · Canada | 2 | Withdrawn | Anelixis Therapeutics | Jun 2024 | 0 |
| NCT04322149Amyotrophic Lateral Sclerosis · United States, Canada | 2 | Completed | Anelixis Therapeutics | Mar 24, 2022 | 54 |
How it is read
Names in the registry
- “AT-1501”, 6 entries
- “Tegoprubart”, 1 entry
- “AT-1501 IV Infusion”, 1 entry
Conditions, from the studies’ own filings
- Kidney Failure, Chronic, 4 studies
- Diabetes Mellitus, Type 1, 2 studies
- Glomerulonephritis, IGA, 1 study
- Amyotrophic Lateral Sclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.